https://www.live-feeds.com/feed/moderna-chasing-holy-grail-of-cancer-preventionContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-chasing-holy-grail-of-cancer-preventionhttps://www.live-feeds.com/feed/moderna-chasing-holy-grail-of-cancer-prevention#u201803Sun, 15 Nov 2026 05:42:14 +0000Moderna is advancing personalized mRNA cancer vaccines designed to prevent recurrence by targeting unique tumor mutations in individual patients. The company's CEO has stated ambitions to surpass Keytruda's commercial success with this approach. Early data shows promise against melanoma, with each vaccine manufactured for a single patient. Analysts are questioning whether the first therapy can secure FDA approval by 2027, while Johns Hopkins researchers note broader promise for both treatment and prevention across cancer types.Why it mattersPersonalized cancer vaccines represent a sh